UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Core Insights - Aptorum Group Limited, DiamiR Biosciences Corp., and Instant NanoBiosensors Co., Ltd. have announced a collaboration to validate INB's automated APOE testing platform for clinical use in DiamiR's laboratory [1][4] Group 1: Collaboration and Testing - DiamiR will compare INB's automated G8 Genotyping Analyzer for APOE testing with its New York State approved APOE test to evaluate performance and suitability for Alzheimer's disease testing [3] - The collaboration aims to introduce an automated testing solution for Alzheimer's disease risk assessment into clinical practice, enhancing testing capabilities and laboratory throughput [4] Group 2: APOE Testing Significance - The APOE gene is the strongest known genetic risk factor for late-onset Alzheimer's disease, with carriers of one copy having a 2-4 times higher risk and those with two copies having an 8-12 times higher risk compared to non-carriers [2][5] - Approximately 15% to 25% of the population has at least one copy of the APOE ε4 allele, and 2% to 5% carry two copies, making APOE testing a crucial tool in clinical management [5] Group 3: Company Backgrounds - DiamiR Biosciences focuses on developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents worldwide [6] - Aptorum Group is a clinical stage biopharmaceutical company dedicated to discovering and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [9] - Instant NanoBiosensors develops advanced biosensor platforms to improve biomedical research and diagnostic workflows, aiming for cost-effective and reliable technologies [10]

Core Viewpoint - Andean Precious Metals Corp. has announced a secondary offering of 7,915,000 common shares at a price of C$10.50 per share, aiming to strengthen its shareholder base and improve trading liquidity [1][3]. Group 1: Secondary Offering Details - The secondary offering will generate aggregate gross proceeds of C$83,107,500 for the Selling Shareholder, PMB Partners LP [1]. - The Underwriters have a one-time option to purchase an additional 15% of the common shares to cover over-allotments [2]. - The net proceeds from the offering will go directly to the Selling Shareholder, with the Company not receiving any proceeds [3]. Group 2: Shareholder and Ownership Structure - Following the secondary offering, the Selling Shareholder will own approximately 47.94% of the outstanding common shares, down from 53.22% [8][9]. - If the Underwriters' option is fully exercised, the Selling Shareholder's ownership will further decrease to 47.15% [9]. Group 3: Strategic Intent - The transaction is intended to attract institutional investors and increase public float, thereby enhancing liquidity without diluting existing shareholders [3][4]. - The Executive Chairman and CEO, Alberto Morales, emphasized his commitment to the Company's strategy and long-term value creation [5]. Group 4: Regulatory and Offering Process - The common shares will be offered publicly in all Canadian provinces and territories, except Québec and Nunavut, and may also be offered to qualified institutional buyers in the U.S. under Rule 144A [6]. - The offering is subject to corporate and regulatory approvals and is expected to close around January 28, 2026 [5]. Group 5: Lock-Up Agreements - The Selling Shareholder has agreed not to sell any common shares for 90 days post-closing, and the Company will also refrain from issuing new shares during this period [7].

Core Insights - DiamiR Biosciences Corp. and Aptorum Group Limited are set to present at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, showcasing innovative blood-based diagnostic tests for brain health and neurodegeneration [1][4] Presentation Details - The presentations will occur on December 3, 2025, at the Hilton San Diego Bayfront, focusing on microRNA classifiers and their role in classifying cognitive impairment stages [2] - Poster 225 will discuss developing microRNA classifiers enriched in brain and inflammation in plasma samples, in collaboration with New York University [2] - Poster 240 will characterize stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs, in collaboration with the University of Pennsylvania [3] Merger Information - Aptorum Group and DiamiR have entered into a definitive agreement for an all-stock merger, with DiamiR becoming a wholly-owned subsidiary of Aptorum upon completion, expected in Q1 2026 [5] - The merger is subject to stockholder approval and customary closing conditions [5] Company Profiles - Aptorum Group is a clinical stage biopharmaceutical company focused on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [6] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents [8]

Registration No. [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTORUM GROUP LIMITED (Exact Name of Registrant as Specified in its Charter) Cayman Islands 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 17 Hanover Square London W1S 1BN, United Kingdom Telephone: +44 20 80929299 (Address, ...

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Dreamland experiencing the largest drop of 80.98% [1] - Other notable declines include Tianruixiang at 46.5%, Zhiling Group at 29.96%, and Mercurity Fintech at 26.69% [1] - The trading volumes for these stocks varied, with Dreamland having a transaction amount of 37.5017 million and Mercurity Fintech at 8.0682 million [1] Group 2 - Dreamland's latest price is reported at 1.160, down by 4.940 [1] - Tianruixiang's latest price is 1.260, down by 1.095 [1] - Zhiling Group's latest price is 1.660, down by 0.710 [1]

Core Viewpoint - Aptorum Group Limited has announced a registered direct offering of 1,000,000 Class A ordinary shares at a price of $2.00 per share, with potential additional gross proceeds of up to $4 million from unregistered warrants [1][3]. Group 1: Offering Details - The offering is expected to generate gross proceeds of $2 million before deducting fees and expenses [3]. - The company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share, which will be exercisable upon issuance and expire in twenty-four months [1][3]. - The closing of the offering is anticipated to occur around October 14, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund expenses related to the merger agreement between Aptorum and DiamiR Biosciences Corp., as well as for general working capital for both companies pending the merger's closing [3]. Group 3: Regulatory Information - The ordinary shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 19, 2023 [4]. - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under applicable securities laws [5].

Core Viewpoint - Aptorum Group Limited announces the addition of Dr. Laura A. Philips to its board of directors following the merger with DiamiR Biosciences Corp, aiming to enhance its strategic initiatives in addressing aging-related diseases [1][3]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [8]. - DiamiR Biosciences is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions, utilizing a proprietary platform technology based on microRNA signatures [9]. Leadership Changes - Dr. Laura A. Philips, co-founder and CEO of Spheryx, Inc., joins Aptorum's board as an independent director, bringing extensive experience in life sciences and technology [2][3]. - Following the merger, Dr. Kira Sheinerman from DiamiR will join the combined board, and Dr. Alidad Mireskandari will assume the role of President and COO [4][5]. Strategic Goals - The merger is expected to strengthen market awareness and execution capabilities for both Aptorum and DiamiR, particularly in the development of tests for Alzheimer's and other brain diseases [3][4]. - The transaction is anticipated to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions [3].